Status:
NOT_YET_RECRUITING
Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy
Lead Sponsor:
Tanta University
Conditions:
Liver Fibroses
HBV (Hepatitis B Virus)
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.
Detailed Description
Hepatitis B virus (HBV) is a serious public health problem worldwide and major cause of chronic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). It was estimated that approximately ...
Eligibility Criteria
Inclusion
- Patients with fibrosis stage (F2\&F3) post chronic HBV infection receiving standard antiviral therapy.
- Age \> 18 and \< 65 years.
Exclusion
- Patients with prior history of liver transplantation.
- Patients with prior history of hepatocellular carcinoma.
- Patients coinfected with HIV or HCV.
- Patients with any malignancies.
- Pregnant and lactating women.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT07145268
Start Date
September 1 2025
End Date
September 1 2026
Last Update
August 28 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.